New Hampshire Medicaid Fee-for-Service (I Prior Authorization Drug Approval Form	FFS) Program
Weight Management Medications	
DATE OF MEDICATION REQUEST: /	/
SECTION I: PATIENT INFORMATION AND MEDICATION F	REQUESTED
LAST NAME:	FIRST NAME:
MEDICAID ID NUMBER:	DATE OF BIRTH:
	— — — — — — — — — — — — — — — — — — —
GENDER: Male Female	
Drug Name	Strength
Dosing Directions	Length of Therapy
SECTION II: PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
SPECIALTY:	NPI NUMBER:
PHONE NUMBER:	FAX NUMBER:
SECTION III: CLINICAL HISTORY	
For Imcivree™ requests, skip to question 16.	
1. Patient's diagnosis:	
2. Is the patient between 12 and 18 years of age (Saxenda [®] , Wegovy [®] , Xenical [®] only)?	
If yes , skip to question 11 .	
3. Is the patient ≥ 16 years of age (Adipex [®] , phentermine, Lomaira [™]) or ≥ 18 years of age (all drugs)?	
 Has the patient failed to lose weight on a low calorie d 1,600 kcal/day for men) AND exercise regimen after at 	
Explain:	
5. Does the patient have a BMI ≥ 30 kg/m ² with no risk fa high risk factor, or two other risk factors?	ctors or ≥ 27 kg/m ² with at least one Yes No
6. Patient's BMI: Weight:	Height: Date:
7. Waist Circumference:	





New Hampshire Medicaid Fee-for-Service (FFS) Program

Prior Authorization Drug Approval Form Weight Management Medications

PATIENT LAST NAME: PATIENT FIRST NAME:
SECTION III: CLINICAL HISTORY (continued)
8. Does the patient have any of the following high-risk factors?
Sleep apnea Coronary heart disease Type 2 diabetes Atherosclerotic disease
9. Does the patient have any of the following risk factors?
Hypertension Gynecologic abnormalities Cigarette smoking Osteoarthritis Gallstone
Stress incontinence Dyslipidemia Age (men > 45 years, women > 55 years or postmenopausal)
Family history of premature heart disease Impaired fasting glucose concentration
10. Are there any contraindications to the use of this drug for this patient?
If yes , explain then skip to question 21 :
11. Is the patient's body weight > 60 kg? Yes No
12. Does the patient's initial BMI correspond to 30 kg/m ² for adults?
13. Is the patient > 95 th percentile on the pediatric growth chart?YesYes
14. Will the patient be maintained on a reduced calorie diet and increased physical activity?
15. Are there any contraindications to the use of this drug for this patient?
If yes , explain, then skip to question 21:
16. Does the patient have a BMI \ge 30 kg/m ² or \ge 95 th percentile on the pediatric growth chart? \Box Yes \Box No
17. Does the patient have a diagnosis of proopiomelanocortin (POMC), proprotein convertase
subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as confirmed by a genetic test?
18. Is the genetic variant "pathogenic, likely pathogenic, or of uncertain significance"?
19. Does the patient have a diagnosis of Bardet-Biedl Syndrome? <i>If yes, select all that apply:</i>
Intellectual impairment Renal anomalies Polydactyly
Retinal degeneration Genital anomalies 20 to the group with the endowing to give the second base second base second base of the endowing to give the second base second base second base of the endowing to give the second base s
20. Is the prescriber an endocrinologist or geneticist, or has one been consulted?
 Is there any additional information that would help in the decision-making process? If additional space is needed, please use a separate sheet.
Baseline body weight: Renewal body weight:
I certify that the information provided is accurate and complete to the best of my knowledge and I understand t that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.
PRESCRIBER'S SIGNATURE: DATE:

